Patent ID: 8895504

Claim:
A derivative of amylin, which is a human amylin analogue, wherein the human amylin analogue comprises an amino acid sequence of formula 1: Xaa 1 -Cys- Xaa 3 -Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala- Xaa 14 -Phe-Leu- Xaa 17 -Xaa 18 -Ser-Ser-Xaa 21 -Asn- Phe- Xaa 24 - Xaa 25 - Xaa 26 -Leu-Xaa 28 -Xaa 29 -Thr- Xaa 31 -Val-Gly-Ser-Asn-Thr-Tyr Formula (1) (SEQ ID No:2) wherein Xaa 1 is deleted or independently selected from Lys, Arg, His and Glu; Xaa 3 is independently selected from Asn and Lys; Xaa 14 is independently selected from Glu, Asn, Gln and Asp; Xaa 17 is independently selected from His, Ser, Gly, Arg and Pro; Xaa 18 is independently selected from His or Arg; Xaa 21 is independently selected from Asp, Asn and Gln; Xaa 24 is independently selected from Glu and Gly; Xaa 25 is independently selected from Ala and Pro; Xaa 26 is independently selected from Pro and Ile; Xaa 28 is independently selected from Ser and Pro; Xaa 29 is independently selected from Ser and Pro; Xaa 31 is independently selected from Glu and Asn; the C-terminal may optionally be derivatized as an amide; wherein a substituent is connected to the amino acid residue Xaa 1 or to Cys in position 2, which substituent comprises an albumin binding moiety.